PRESS RELEASES

FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

SHANGHAI, China, Jan. 25, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that U.S. Food and Drug Administration (FDA) has granted toripalimab Fast Track designation for the first-line treatment of mucosal melanoma. Meanwhile, the FDA has also approved the Investigational New Drug (IND) application for a global Phase III trial of Toripalimab in combination with Axitinib versus Pembrolizumab for the first-line treatment of patients with advanced mucosal melanoma (Combination Clinical Trial).

About Toripalimab
Toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing in China. More than thirty company-sponsored clinical studies covering more than fifteen indications have been conducted globally, including in China and the United States. On December 17, 2018, Toripalimab obtained a conditional approval from the National Medical Products Administration (the “NMPA”) for the second-line treatment of unresectable or metastatic melanoma. Toripalimab was included in the 2019 and 2020 Guidelines of Chinese Society of Clinical Oncology (CSCO) for the Diagnosis and Treatment of Melanoma. Two supplemental New Drug Applications (NDAs) of Toripalimab for the third-line treatment of recurrent/metastatic nasopharyngeal carcinoma and the second-line treatment of metastatic urothelial carcinoma were accepted by the NMPA in April and May 2020, respectively. Both supplemental NDAs received priority review designations from the NMPA in July 2020. In addition, Toripalimab for the treatment of recurrent/metastatic nasopharyngeal carcinoma was granted the Breakthrough Therapy Designation (BTD) by the FDA in September 2020. In December 2020, Toripalimab was included in the updated National Reimbursement Drug List (NRDL) (2020 Edition).

About Combination Clinical Trial
The Combination Clinical Trial is an international, multi-center, randomized Phase III study designed to evaluate the efficacy and safety of Toripalimab in combination with Axitinib versus Pembrolizumab as a first-line treatment in patients with unresectable, locally advanced or metastatic mucosal melanoma. The trial intends to enroll 220 patients who will be randomized at 1:1 ratio into two study arms. The primary endpoint of the Combination Clinical Trial is progression-free survival (PFS). The secondary endpoints include objective response rate (ORR), duration of response (DOR), overall survival (OS), and safety.

Mucosal melanoma is a subtype of melanoma with mucosal origin. Compared with cutaneous melanoma, mucosal melanoma is less responsive to traditional chemotherapy and immunotherapy, and thus remains an unmet medical need. Toripalimab and Axitinib combination was the world’s first clinical application of PD-1 checkpoint blockade with a VEGFR inhibitor for the treatment of mucosal melanoma in a Phase Ib study (NCT03086174). The results of the study were published in the Journal of Clinical Oncology in August 2019. The study showed that the combination of Toripalimab with Axitinib in the first-line setting achieved an ORR of 48.3% and a disease control rate (DCR) of 86.2% for advanced mucosal melanoma with a manageable safety profile. The median progression-free survival (mPFS) was 7.5 months. In March 2020, Toripalimab in combination with Axitinib for the treatment of mucosal melanoma was granted the Orphan-Drug Designation (ODD) by the FDA.

About Fast Track Designation (FTD)
The FTD aims to facilitate the development and accelerate the review process of treatments for serious or life-threatening diseases or conditions that remain unmet clinical needs. The FTD is designed to make important new drugs accessible to patients faster. According to FDA regulations, drugs that receive FTDs will be granted an accelerated review process through various forms, including but not limited to (1) more frequent interactions and meetings with the FDA to discuss drug development and clinical trial design; (2) eligibility for priority review and accelerated approval after meeting relevant criteria; (3) rolling review, which means instead of waiting until all sections of the NDA are completed, a company can submit completed sections of its biologic license application (BLA) or new drug application (NDA) for review on a rolling basis.

The FTD will significantly accelerate the research, development, and marketing of Toripalimab in the United States. This marks another important milestone, after Toripalimab was granted the ODD and the BTD by the FDA.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HK: 1877; SH: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 27 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology Chinese Academy of Science and Eli Lilly to co-develop JS016, China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2, which has entered clinical trials and is now a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Contact Information

IR Team:
Junshi Biosciences
[email protected]
+ 86 021-2250 0300

Solebury Trout
Bob Ai
[email protected]
+ 1 646.378-2926

PR Team:
Junshi Biosciences
Zhi Li
[email protected]
+ 86 021-6105 8800

Latest News

Informa Markets ขับเคลื่อนการฟื้นตัวทางเศรษฐกิจด้วยการกลับมาจัดงานจัดแสดงอย่างปลอดภัยและประสบความสำเร็จ

Informa Markets นำลูกค้ากลับสู่งานกิจกรรมสด ผลักดันการฟื้นตัวทางเศรษฐกิจ การเชื่อมต่อและนวัตกรรมผ่านแนวทางการทำงานร่วมกันและเป็นพื้นฐานเพื่อความปลอดภัย ออร์แลนโด, Fla., March 06, 2021 (GLOBE NEWSWIRE) — ในขณะที่อุตสาหกรรมและเศรษฐกิจทั่วโลกมองหาโอกาสในการฟื้นฟูธุรกิจใหม่หลังจากการระบาดของโควิด-19 Informa Markets ผู้จัดงานระดับโลกที่สร้างแพลตฟอร์มสำหรับอุตสาหกรรมที่หลากหลายเพื่อค้าขาย เชื่อมต่อและเติบโต ได้เปิดตัวงาน MAGIC Pop-Up Orlando ตั้งแต่วันที่ 9-11 กุมภาพันธ์ที่ Orange County Convention Center โดย ‘Pop-Up’ เป็นงานแฟชั่นระดับภูมิภาคที่มีขนาดเล็กกว่างานแฟชั่นที่สำคัญซึ่งโดยปกติจะจัดขึ้นปีละ 2 ครั้งในลาสเวกัส เนวาดา เป็นโอกาสสำหรับ ‘ร้านค้าครบวงจร’ ที่ครอบคลุมภาคส่วนต่างๆ ของอุตสาหกรรมแฟชั่น ซึ่งเป็นหนึ่งในหลายอุตสาหกรรมได้รับผลกระทบอย่างหนักจากผลกระทบทางเศรษฐกิจอันร้ายแรงจากการระบาด เพื่อค้นหาแบรนด์ใหม่ๆ สร้างเครือข่ายอย่างปลอดภัยกับผู้ค้าปลีกที่มีแนวทางเดียวกัน และสร้างรายได้ที่จำเป็นอย่างมาก Informa Markets Fashion ทำหน้าที่เป็นแพลตฟอร์มการจัดหาเสื้อผ้าบุรุษ เสื้อผ้าสตรี รองเท้าและเครื่องแต่งกายตามชื่อของมัน ได้ทำการสำรวจลูกค้าในช่วงปลายปี 2020 เพื่อระบุวิธีที่ดีที่สุดในการตอบสนองความต้องการของชุมชนแฟชั่น ซึ่งความต้องการที่จะกลับมาเพื่อจัดแสดงสินค้าในไตรมาสที่ 1 ปี […]

Amlan International Names Wade Robey as Vice President, Marketing and Product Development

Wade Robey CHICAGO, March 04, 2021 (GLOBE NEWSWIRE) — Amlan International, the animal health business of Oil-Dri Corporation of America and a global leader in mineral-based feed additives that improve the intestinal health and efficiency of poultry and livestock, has named Wade Robey as Vice President, Marketing and Product Development. Wade’s appointment as the global […]

Constellation Brands to Report Full Fiscal Year and Fourth Quarter 2021 Financial Results; Host Conference Call April 8, 2021

VICTOR, N.Y., March 04, 2021 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today it will report financial results for its full fiscal year and fourth quarter ended February 28, 2021, on Thursday, April 8, 2021, before the open of the U.S. markets. A conference call to […]

Informa Markets Drives Economic Recovery with Safe and Successful Return to the Show Floor

Informa Markets makes a customer-driven return to live events, driving economic recovery, connection and innovation through a collaborative and foundational approach to safety ORLANDO, Fla., March 04, 2021 (GLOBE NEWSWIRE) — As industries and economies around the world look for opportunities to rebuild business in the wake of the COVID-19 pandemic, Informa Markets, a global […]